Vertex Pharmaceuticals Incorporated (VRTX) — RQD Stock Rating Cockpit
Vertex Pharmaceuticals Incorporated (VRTX) earns a Roarable Rating of B- (Buy) with 71/100 RQD Confidence. High-quality cash engine (86% profit margin, 20% return on capital) with steady institutional support. Even if the broader market gets choppy, the company’s underlying cash engine and big-money support put the odds in buyers’ favor.
Real cash coming in backs up reported profits (86% profit margin and healthy balance-sheet cushion).
Big funds and company insiders are mostly holding steady without aggressive buying or panic selling.
Clean SEC fine-print check with low hidden accounting risk and favorable interest-rate weather.
2-of-3 JEV AI Jury Bullish on VRTX
20.0% ROIC with 86.2% gross margin and 2.33% FCF yield.
Altman-Z 13.86 and Piotroski 8/9 pass balance-sheet audit.
Put/Call 0.65x with 22/40 institutional & insider flow.
- ✓Strong cash generator (86% profit margin)—profits are backed by real money, not accounting tricks.
- ✓Clean SEC annual filing review with no major hidden accounting time-bombs.
- !Broader market pullbacks can still drag down strong stocks in the short run.
Today's Top 3 RQD Strong Buys & Whale Accumulation Setups (Live VRTX Tape Review)
- ✓Live breakdown of today’s highest-scoring RQD Green-Light breakouts
- ✓1 urgent Red-Light accounting trap to cut from your watchlist immediately
- ✓Bring any ticker to live Q&A—we run it through the 5-Pillar RQD Radar on screen
VRTX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +8.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on VRTX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for VRTX. Explore sector supply chains on /butterfly.
VRTX Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDShould I buy, hold, or sell VRTX stock right now?
Vertex Pharmaceuticals Incorporated (VRTX) currently earns a Roarable Rating of B- (Buy — BUY) with 71/100 RQD Confidence. High-quality cash engine (86% profit margin, 20% return on capital) with steady institutional support.
What is VRTX's 12-month price target and RQD AI Jury consensus?
VRTX's 12-month base price target is $571.59 (range $442.8 to $674.48), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.